Zydus Cadila launches COVID-19 drug Remdesivir in India

Priced at ₹2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.

August 13, 2020 10:32 am | Updated 10:37 am IST - New Delhi

Drug firm Zydus Cadila said the drug will be made available across India (photo for representation only).

Drug firm Zydus Cadila said the drug will be made available across India (photo for representation only).

Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market.

Priced at ₹2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.

The company said the drug will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating COVID-19 patients.

Remdac is the most affordable drug as we would like to enable patients to have access to this critical drug in the treatment of COVID-19, Cadila Healthcare Managing Director Dr. Sharvil Patel said.

Through the course of this pandemic, the company’s efforts have been focused on supporting people in this healthcare crisis, whether it is through developing vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests available or exploring new treatment options, Dr. Patel added.

In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorisation by the U.S. Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19.

The active pharmaceutical ingredient (API) for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat.

Zydus Cadila’s vaccine candidate ZyCov-D is now in phase II of the clinical trials.

Shares of Cadila Healthcare, the listed entity of the group, were trading at ₹387 apiece on BSE, 0.44% higher against their previous close.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.